“Surge in Leadless and AI-Integrated Pacemakers”
- Leadless pacemakers, which eliminate the need for leads and are implanted directly into the heart, offer benefits such as reduced risk of infection and shorter recovery times.
- For instance, Abbott's dual-chamber leadless pacemaker system, AVEIR, received FDA approval in July 2023, marking a significant milestone in minimally invasive cardiac care
- Additionally, the integration of artificial intelligence into pacemakers is enhancing device performance and patient outcomes
- AI algorithms enable real-time monitoring and personalized adjustments to pacing, improving the management of arrhythmias and other cardiac conditions
- These innovations are not only improving patient care but also expanding the market's reach, as they cater to a growing demand for advanced cardiac solutions
